The total return over the past 12 months is -67.65% vs. +16.94% for the S&P 500. So far it's up -43.45% this year. Includes price appreciation + reinvested dividends.
| Category | 1Y (TTM) | 3Y | 5Y | 10Y | 15Y | 20Y |
|---|---|---|---|---|---|---|
| Price CAGR | (67.65%) | (4.03%) | (20.07%) | (20.53%) | N/A | N/A |
| Total Return CAGR | (67.65%) | (4.03%) | (20.07%) | (20.53%) | N/A | N/A |
| Revenue CAGR | +7.52% | +3.03% | (0.26%) | N/A | N/A | N/A |
| Net Income CAGR | N/A | N/A | N/A | N/A | N/A | N/A |
| EPS CAGR | N/A | N/A | N/A | N/A | N/A | N/A |
| Free Cash Flow CAGR | N/A | N/A | N/A | N/A | N/A | N/A |
| Operating Cash Flow CAGR | N/A | N/A | N/A | N/A | N/A | N/A |
| Dividends CAGR | N/A | N/A | N/A | N/A | N/A | N/A |
Visualize historical growth rates over rolling horizons. Use the dropdown to select different metric vectors.
Akebia Therapeutics, Inc. (AKBA)
| Year | Start price | End price | AKBA Return | SPY Return | Outperformance |
|---|---|---|---|---|---|
| 2026(YTD) | $1.61 | $0.91 | (43.45%) | +14.51% | (57.96%) |
| 2025 | $1.90 | $1.61 | (15.26%) | +17.72% | (32.98%) |
| 2024 | $1.24 | $1.90 | +53.23% | +24.89% | +28.34% |
| 2023 | $0.58 | $1.24 | +114.90% | +26.19% | +88.71% |
| 2022 | $2.26 | $0.58 | (74.47%) | (18.17%) | (56.30%) |
| 2021 | $2.80 | $2.26 | (19.29%) | +28.74% | (48.03%) |
| 2020 | $6.32 | $2.80 | (55.70%) | +18.37% | (74.07%) |
| 2019 | $5.53 | $6.32 | +14.29% | +31.22% | (16.93%) |
| 2018 | $14.87 | $5.53 | (62.81%) | (4.56%) | (58.25%) |
| 2017 | $10.41 | $14.87 | +42.84% | +21.70% | +21.14% |
Start and end prices are split-adjusted closing prices. Total return includes reinvested dividends, so it can differ from the price change.
